• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Refractec promotes Frinzi to chief operating officer

Article

Refractec Inc. announces the promotion of Thomas G. Frinzi to the newly created position of chief operating officer to oversee the company?s growing global operations. Frinzi, formerly senior vice president of sales and marketing, will add clinical, regulatory affairs, and quality assurance to his sales and marketing responsibilities. He continues to report directly to President and CEO Mitchell B. Campbell.

Chicago-Refractec Inc. announces the promotion of Thomas G. Frinzi to the newly created position of chief operating officer to oversee the company’s growing global operations. Frinzi, formerly senior vice president of sales and marketing, will add clinical, regulatory affairs, and quality assurance to his sales and marketing responsibilities. He continues to report directly to President and CEO Mitchell B. Campbell.

“Tom’s broad experience in bringing ophthalmic and other medical devices to global markets makes him the ideal person to oversee Refractec’s day-to-day operations,” said Campbell. “Elevating Tom's role in the company will facilitate the continued growth of our company and its core technology and I look forward to working with him to expand our business.”

Since joining Refractec in 2000, Frinzi has led the development of global sales and marketing teams to commercialize the company’s latest technology, NearVision CK (conductive keratoplasty).

Frinzi, who began his career at Johnson & Johnson, is a veteran of the ophthalmic and medical device industries with more than 25 years of experience. Before joining Refractec’s executive management team, he served as vice president of sales at Bausch & Lomb, managing numerous product launches focused on growth and expansion of the ophthalmic market. His ophthalmic career also includes long tenures at Chiron Vision Corp. and Iolab Corp.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
© 2024 MJH Life Sciences

All rights reserved.